Trends in chemotherapy use in neuroendocrine neoplasms: One step beyond guidelines

#3403

Introduction: The therapeutic landscape of neuroendocrine neoplasms (NENs) is constantly evolving. Current guidelines reflect the complexity of treatment sequences and mainly incorporate evidence from phase 3 clinical trials. Chemotherapy (CT) is a valuable option for patients with lung, pancreatic, and high-grade NENs, but proper phase 3 randomized studies are an unmet need. Nevertheless, several phase 2 studies with CT have been presented and published in the last year, with impact in both clinical practice and guidelines.

Aim(s): In the present study, we review CT trends in the last 10 years in the field of NENs.

Materials and methods: All CT treatments administered at our institution between June 2011 and June 2021 were reviewed. All patients with NENs and at least one cycle of oral or intravenous treatment were included in the analysis. Treatment scheduled considered were: Platinum-etoposide (PE) (cisplatin and carboplatin), adenocarcinoma-like (ADK-like) (FOLFOX, FOLFIRI), Streptozocin-5FU (S5FU), and capecitabine-temozolomide (CAPTEM).

Conference:

Presenting Author:

Authors: Hernando J, Garcia-Diaz H, Bellas Fernandez L, Garcia Alvarez A, Roca M,

Keywords: Chemotherapy, CAPTEM, GUIDELINES,